our analysis demonstrates that ifn alfa-2b offers substantial clinical and cost advantages to patients with hairy cell leukemia and that the introduction of this therapy using novel biotechnology furthers the health care community 's commitment to cost containment .
C0021735
ifn alfa-2b
C0023443
hairy cell leukemia